John Connaughton Sells 1,441,236 Shares of Iqvia Holdings Inc (IQV) Stock

Iqvia Holdings Inc (NYSE:IQV) Director John Connaughton sold 1,441,236 shares of Iqvia stock in a transaction on Friday, June 15th. The stock was sold at an average price of $103.00, for a total value of $148,447,308.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of NYSE:IQV opened at $105.61 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.16 and a current ratio of 1.16. The stock has a market cap of $21.64 billion, a price-to-earnings ratio of 24.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.64. Iqvia Holdings Inc has a 1 year low of $87.45 and a 1 year high of $110.67.

Iqvia (NYSE:IQV) last issued its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $1.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.07. The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.42 billion. Iqvia had a net margin of 13.07% and a return on equity of 13.35%. Iqvia’s revenue for the quarter was up 34.1% compared to the same quarter last year. analysts anticipate that Iqvia Holdings Inc will post 5.07 EPS for the current fiscal year.



A number of large investors have recently modified their holdings of the business. Private Capital Group LLC grew its position in shares of Iqvia by 177.0% during the first quarter. Private Capital Group LLC now owns 1,061 shares of the medical research company’s stock worth $104,000 after buying an additional 678 shares in the last quarter. Point72 Asia Hong Kong Ltd acquired a new position in shares of Iqvia during the first quarter worth about $124,000. Focused Wealth Management Inc acquired a new position in shares of Iqvia during the fourth quarter worth about $166,000. Valeo Financial Advisors LLC acquired a new position in shares of Iqvia during the fourth quarter worth about $170,000. Finally, TLP Group LLC grew its position in shares of Iqvia by 1,476.7% during the first quarter. TLP Group LLC now owns 2,034 shares of the medical research company’s stock worth $200,000 after buying an additional 1,905 shares in the last quarter. Institutional investors own 89.47% of the company’s stock.

Several brokerages recently issued reports on IQV. Zacks Investment Research upgraded shares of Iqvia from a “strong sell” rating to a “hold” rating in a report on Friday, March 23rd. ValuEngine lowered shares of Iqvia from a “buy” rating to a “hold” rating in a report on Tuesday, April 3rd. SunTrust Banks upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a report on Wednesday, March 7th. Goldman Sachs Group upgraded shares of Iqvia from a “neutral” rating to a “buy” rating in a report on Friday, April 13th. Finally, Argus boosted their price objective on shares of Iqvia from $110.00 to $112.00 and gave the company a “buy” rating in a report on Monday, April 9th. Six investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $110.47.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Insider Buying and Selling by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply